Clinical Trials Logo

Pediatric ALL clinical trials

View clinical trials related to Pediatric ALL.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05645133 Terminated - Healthy Clinical Trials

QPlus Pediatric Reference Interval

Start date: February 27, 2023
Phase:
Study type: Observational

Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.

NCT ID: NCT03043430 Terminated - Anxiety Clinical Trials

Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients

Start date: May 2016
Phase: Phase 4
Study type: Interventional

Investigators plan to conduct a randomized, double-blinded, controlled study among pediatric patients requiring minor procedures in the Emergency Department setting. Patients will be randomized to one of two arms of intranasal treatments: ketamine 1.0 mg/kg (K) or midazolam 0.3 mg/kg (M). The primary outcome will be change in anxiety using the Modified Yale Preoperative Anxiety Scale (mYPAS).

NCT ID: NCT02989675 Terminated - Critical Illness Clinical Trials

SugarFACT - Sugar Requirements For African Children Trial

Start date: December 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the impact of dextrose administration in severely sick children admitted to hospital with low-glycaemia. The problem: Mortality in children remains high in sub-Saharan African hospitals. While antimalarial drugs, antibiotics and other definitive treatments are well understood, the role of emergency care with supportive therapies such as maintaining normal glucose and electrolyte balances, has been given limited attention. Hypoglycaemia is common in children admitted to hospital in low-income settings. The current definition of hypoglycaemia is a blood glucose level of less than 2.5mmol/l. Outcomes for these children are poor, with a mortality rate of up to 42%. An increased mortality has also been reported among acutely ill children with low-glycaemia, defined as a blood glucose level of 2.5-5.0mmol/l. The reason for increased mortality rates is not fully understood. Study objective: To determine the impact on mortality of a raised treatment cut-off level for paediatric hypoglycaemia, from 2.5mmol/l to 5.0mmol/l. Methodology: Severely ill children admitted to two central Malawian hospitals; Queen Elisabeth Central Hospital, Blantyre and Zomba Central Hospital, with low-glycaemia (2.5-5.0mmol/l) will be randomised into intervention or control groups. The intervention group will be treated with an intravenous bolus of 10% dextrose 5ml/kg followed by a dextrose infusion in addition to standard care while the control group will receive standard care only. Children will be followed until discharge from hospital or death. Primary end-point is in-hospital mortality.